Australia and New Zealand Sarcoma Association
Formerly known as the Australasian Sarcoma Study Group
and the Australian Sarcoma Group
  • About Us
    • About ANZSA
    • Board and CEO
    • Consumer Advisory Panel
    • Strategic Plan
    • Recognition and Awards Program
  • About Sarcoma
    • What is Sarcoma?
      • Soft Tissue Sarcoma
      • Bone Sarcoma
    • Life After Treatment
    • Seeking Second Opinion
    • Find a Sarcoma Specialist
    • Patient and Carer Sarcoma Information
    • Sarcoma Stories
    • Sarcoma in Aboriginal and Torres Strait Islander
  • Research
    • Our Sarcoma Research
    • About Sarcoma Research
    • Clinical Trials and Studies
    • Sarcoma Research Grant Program
    • Frequently Asked Questions
    • Publications
  • Support Us
    • Fundraise for Us
    • Donate in Memory
    • Leave a Bequest
    • Partner with Us
  • Sarcoma Guidelines
    • Preamble
    • Executive Summary
    • Plain Language Summary
    • Topic 1: Treatment at Specialised Sarcoma Centre
    • Topic 2: Retroperitoneal Sarcoma
    • Topic 3: Paediatric/AYA Sarcoma
    • Appendices
  • Shop
  • Events and News
    • News
    • Newsletters
  • ASM 2023
    • 2023 Annual Scientific Registration
    • Abstract/Poster Submissions
    • 2023 Guest Speakers
    • Program
  • Membership
    • Membership
  • Contact Us
Make a Donation
Members Login
Sarcoma Guidelines

Sarcoma Guidelines

  1. Preamble
  2. Executive Summary
  3. Plain Language Summary
  4. Topic 1: Treatment at Specialised Sarcoma Centre
  5. Topic 2: Retroperitoneal Sarcoma
  6. Topic 3: Paediatric/AYA Sarcoma
  7. Appendices

Topic 3: Paediatric/AYA Sarcoma

 

The ANZSA Sarcoma Working Party has identified paediatric/adolescent young adult (AYA) sarcoma as a topic to be addressed. This series of guidelines focuses particularly on treatment of Ewings Sarcoma and Rhabdomyosarcoma.

The guideline questions are as follows:

  1. Does delayed surgical resection of the primary tumour impact on outcome for pelvic Ewing sarcoma?
  2. Does the addition of high-dose chemotherapy have an impact on outcome of Ewing sarcoma compared to standard chemotherapy alone?
  3. Does the addition of high-dose chemotherapy have an impact on outcome of Rhabdomyosarcoma compared to standard chemotherapy alone?

 

Australia and New Zealand Sarcoma Association
Formerly known as the Australasian
Sarcoma Study Group and the Australian
Sarcoma Group

Australia and New Zealand Sarcoma Association
VCCC
Level 1
305 Grattan Street
Melbourne Victoria 3000
Australia

T +61 437 880 835
E contact@sarcoma.org.au
The Australia and New Zealand
Sarcoma Association is registered
as a charity with the Australian
Charities and Not-for-profits
Commission ABN 73 132 759 525
Registered Charity
© 2023 All rights reserved | ANZSA receives funding from the Australian Government through Cancer Australia | Terms & Conditions | Privacy Policy | Contact | Website by Echo3